Literature DB >> 1233244

Metabolism and excretion of methylproscillaridin by man.

N Rietbrock, R Staud.   

Abstract

0.5 mg 3H-proscillaridin-4-methylether was administered orally to 5 healthy males. Maximum plasma levels of total radioactivity were reached after one to two hours. In two subjects a second peak was observed between 6 and 12 hours. The plasma half life of total radioactivity was 51 hours. 20% and 56% respectively of the dose were eliminated in urine and faeces during the following 7 days. 55% of the total radioactivity in plasma, 80% in urine and 20% in faeces consisted of CHC13-insoluble compounds. 50-60% of the latter in plasma and urine could be hydrolysed by beta-glucuronidase. More than 90% of the split products were identified as conjugates of methylproscillaridin. TLC-separation of the CHC13-soluble fractions of plasma and urine yielded two unidentified metabolites, P2 and P3, as the main compounds, besides methylproscillaridin, proscillaridin and scillarenin. In faeces more than 90% of the non-polar fraction was identified as methylproscillaridin. Shortly after administration of 3H-methylproscillaridin, the radioactivity in plasma consisted mainly of CHC13-insoluble conjugates and of the metabolite P2.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233244     DOI: 10.1007/bf00562317

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  [CONJUGATION OF CARDENOLIDE GENINS WITH SULFURIC ACID OR GLUCURONIC ACID].

Authors:  I HERRMANN; K REPKE
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1964-06-22

2.  Metabolism and excretion of digitoxin in man.

Authors:  H F Vöhringer; N Rietbrock
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

3.  6Beta-hydroxy-3-epidigitoxigenin--the major metabolite of digitoxigenin by rabbit liver homogenates.

Authors:  W H Bulger; S J Stohs; D M Wheeler
Journal:  Biochem Pharmacol       Date:  1974-03-01       Impact factor: 5.858

4.  [Plasma levels, elimination and cumulation of proscillaridin in renal failure (author's transl)].

Authors:  G G Belz; W J Brech
Journal:  Klin Wochenschr       Date:  1974-07-01

5.  Pharmacokinetics and metabolism of digoxigenin-mono-digitoxoside in man.

Authors:  J Kuhlmann; U Abshagen; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  The cardioactivity of digitoxin metabolites.

Authors:  H Mann; T Peters
Journal:  Eur J Pharmacol       Date:  1971-04       Impact factor: 4.432

7.  [Therapeutic experiences with a new cardiac glycoside: proscillaridin A].

Authors:  G Meier; G Wagner
Journal:  Med Welt       Date:  1965-08-28

8.  [Clinical-experimental study on the characterization of a cardiac glycoside].

Authors:  J Hänel; G Meiffert
Journal:  Med Welt       Date:  1966-06-25

9.  A quantitative method for the chromatographic separation of 17-oxo steroid sulphates from 17-oxo steroid glucuronides with observations on the behaviour of conjugated corticosteroids on the same system.

Authors:  J J BARLOW; A E KELLIE
Journal:  Biochem J       Date:  1959-01       Impact factor: 3.857

10.  [Partly synthetic cardiac glycoside derivatives with improved enteral effectiveness. 28. Cardiac glycosides].

Authors:  F Kaiser
Journal:  Planta Med       Date:  1971       Impact factor: 3.352

View more
  3 in total

1.  Excretion of methylproscillaridin in patients with a biliary fistula.

Authors:  R Staud; N Rietbrock; H P Fassbender
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

2.  Proscillaridin activity in portal and peripheral venous blood after oral administration to man.

Authors:  K E Andersson; B Bergdahl; H Dencker; G Wettrell
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

Review 3.  Digitalis pharmacokinetics and therapy with respect to impaired renal function.

Authors:  P Kramer
Journal:  Klin Wochenschr       Date:  1977-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.